Leadership Overview
Biogen has 9 executives leading key functions including strategy, financial oversight, research operations, commercial execution, legal compliance, medical affairs, and regional market management.
Committed to advancing neuroscience, Biogen delivers transformative therapies for patients suffering from serious neurological and neurodegenerative diseases through rigorous scientific innovation and global commercial excellence.
Committed to advancing neuroscience, Biogen delivers transformative therapies for patients suffering from serious neurological and neurodegenerative diseases through rigorous scientific innovation and global commercial excellence.
Leadership Roles at Biogen
Christopher Viehbacher - President & Chief Executive Officer
Christopher Viehbacher, the President & Chief Executive Officer at Biogen, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the global development of therapies for neurodegenerative diseases, the President & Chief Executive Officer ensures alignment between research initiatives and commercial objectives. This leadership role involves navigating complex regulatory landscapes while driving sustainable growth across international markets. By prioritizing innovation in biologics and gene-based therapies, Christopher Viehbacher directly impacts the company's ability to address unmet patient needs. Ultimately, Viehbacher secures the competitive positioning of the firm within the global biotechnology sector, fostering a culture of scientific excellence and operational efficiency that supports the delivery of life-changing treatments to patients worldwide.

Robin Kramer - Chief Financial Officer
Robin Kramer, the Chief Financial Officer at Biogen, manages the fiscal health and capital allocation strategies of the enterprise. Overseeing financial planning, reporting, and investor relations, the Chief Financial Officer ensures the company maintains the necessary resources to fund high-stakes research in neuroscience. This leadership role involves optimizing cost structures to support the commercialization of therapies for multiple sclerosis and rare neurological disorders. By maintaining rigorous financial discipline, Robin Kramer directly impacts the long-term viability of the business model. Ultimately, Kramer provides the economic framework required to sustain the company's commitment to scientific discovery, ensuring that capital investments align with the strategic goals of the organization while delivering consistent value to shareholders and stakeholders across the global pharmaceutical landscape.

Nicholas Colafemina - Chief of Staff To the Chief Financial Officer. Director
Nicholas Colafemina, the Chief of Staff To the Chief Financial Officer. Director at Biogen, manages the administrative and strategic priorities of the finance department. Overseeing the execution of financial initiatives, the Chief of Staff To the Chief Financial Officer. Director ensures that the office of the CFO operates with maximum efficiency. This leadership role involves synthesizing complex financial data into actionable insights for executive decision-making. By facilitating communication across the finance organization, Nicholas Colafemina directly impacts the accuracy and speed of corporate reporting. Ultimately, Colafemina supports the financial stability of the company, ensuring that the strategic vision of the CFO is implemented effectively across all departments, thereby maintaining the fiscal integrity required to support the company's ongoing investment in neuroscience and biotechnology innovation.
Takatsugu Den - President & Managing Director
Takatsugu Den, the President & Managing Director at Biogen, oversees the strategic operations and market expansion within the Asia-Pacific region. Directing the commercial activities and local partnerships, the President & Managing Director ensures that the company's portfolio of neurological therapies reaches patients in these critical markets. This leadership role involves adapting global strategies to meet the specific regulatory and healthcare requirements of the region. By fostering strong relationships with local stakeholders, Takatsugu Den directly impacts the growth of the company's footprint in the area. Ultimately, Den drives the regional execution of the corporate mission, ensuring that the company's commitment to neuroscience innovation is effectively translated into improved patient outcomes across diverse and rapidly evolving healthcare systems in the Asia-Pacific territory.

Alisha Alaimo - President & Head of North America
Alisha Alaimo, the President & Head of North America at Biogen, directs the commercial strategy and operational execution across the North American market. Overseeing the sales, marketing, and patient access teams, the President & Head of North America ensures that the company's therapies for multiple sclerosis and other disorders are accessible to those in need. This leadership role involves navigating the complex healthcare landscape to drive market share and revenue growth. By implementing targeted commercial initiatives, Alisha Alaimo directly impacts the company's performance in its largest market. Ultimately, Alaimo strengthens the company's competitive position, ensuring that the organization's commitment to scientific excellence is reflected in the successful delivery of high-value treatments to patients throughout the North American region.

Evelyn Reuss - Research Chief of Staff
Evelyn Reuss, the Research Chief of Staff at Biogen, coordinates the operational workflows within the research and development division. Overseeing the integration of scientific projects, the Research Chief of Staff ensures that laboratory efforts remain synchronized with the broader mission of discovering treatments for neurodegenerative conditions. This leadership role involves facilitating communication between scientific teams and executive leadership to accelerate the pipeline of biologics. By streamlining internal processes, Evelyn Reuss directly impacts the speed and efficiency of drug development cycles. Ultimately, Reuss optimizes the research environment, allowing scientists to focus on breakthrough discoveries in neuroscience while maintaining strict adherence to project timelines and corporate objectives, thereby strengthening the company's position as a leader in the biotechnology industry.
Kristin Melaugh - Chief of Staff Commercial, SYFOVRE and EMPAVELI
Kristin Melaugh, the Chief of Staff Commercial, SYFOVRE and EMPAVELI at Biogen, directs the commercialization strategy for specific therapeutic assets. Overseeing the market access and launch activities for these critical products, the Chief of Staff Commercial, SYFOVRE and EMPAVELI ensures that patients gain timely access to essential treatments. This leadership role involves coordinating cross-functional teams to maximize the impact of commercial efforts in the rare disease space. By aligning marketing and sales strategies with clinical data, Kristin Melaugh directly impacts the revenue growth associated with these key therapies. Ultimately, Melaugh drives the successful market penetration of these products, ensuring that the company's commitment to addressing rare neurological disorders translates into tangible clinical outcomes and robust commercial performance within the competitive pharmaceutical market.
Michael Parini - Chief Legal Officer
Michael Parini, the Chief Legal Officer at Biogen, directs the legal and compliance framework governing the company's global operations. Overseeing intellectual property protection, regulatory adherence, and corporate governance, the Chief Legal Officer ensures that the organization operates within the highest ethical and legal standards. This leadership role involves managing complex litigation and licensing agreements that are vital to the commercialization of gene-based therapies. By mitigating legal risks, Michael Parini directly impacts the company's ability to innovate and bring new treatments to market. Ultimately, Parini safeguards the assets and reputation of the firm, providing the necessary legal foundation for the company to pursue its mission of transforming the lives of patients suffering from serious neurological diseases on a global scale.

Daniel Quirk - Chief Medical Officer
Daniel Quirk, the Chief Medical Officer at Biogen, leads the clinical development and medical affairs strategy for the entire product portfolio. Overseeing the design and execution of clinical trials, the Chief Medical Officer ensures that all therapies meet rigorous safety and efficacy standards before reaching patients. This leadership role involves engaging with the medical community to communicate the clinical value of treatments for spinal muscular atrophy and other disorders. By bridging the gap between scientific research and clinical practice, Daniel Quirk directly impacts the successful adoption of new therapies. Ultimately, Quirk ensures that the company's medical strategy remains patient-centric, driving the development of evidence-based solutions that address the most challenging neurological conditions in the global healthcare market.
Explore Leadership Teams in Manufacturing
Johnson & Johnson is a global healthcare company that develops pharmaceuticals and medical technologies. It provides innovative medicines, surgical products, and medical devices used in areas such as oncology, immunology, neuroscience, and cardiovascular care, serving healthcare providers and patients worldwide.
Company Leadership
LG
RV
PA
Zoetis discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. It markets to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company is headquartered in Parsippany, New Jersey.
Company Leadership AM
LP
RV
CF
PCI Pharma Services is a global Contract Development and Manufacturing Organization (CDMO) that provides innovative solutions in sterile and non-sterile services, clinical trial services, and commercial packaging technology. The company is dedicated to delivering life-changing therapies through intelligence, ingenuity, and innovation, ensuring the highest levels of quality and regulatory compliance. With a strong focus on collaboration, PCI supports clients throughout the entire product lifecycle, from early-stage development to commercialization. Operating over 38 GMP facilities worldwide, PCI Pharma Services is committed to advancing healthcare and improving patient lives.
Company Leadership BK
HL
AH
Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab's proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.
Company Leadership JH
AC